Clinical trial • Phase I • Oncology
Sigvotatug Vedotin for Esophageal cancer|Pancreatic cancer|Skin cancer|Gastric cancer|Head and neck cancer|Ovarian cancer|Non-small cell lung cancer|Cervical cancer|Breast cancer|Bladder cancer
Phase I trial of Sigvotatug Vedotin for Esophageal cancer|Pancreatic cancer|Skin cancer|Gastric cancer|Head and neck cancer|Ovarian cancer|Non-small cell…
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Esophageal cancer|Pancreatic cancer|Skin cancer|Gastric cancer|Head and neck cancer|Ovarian cancer|Non-small cell lung cancer|Cervical cancer|Breast cancer|Bladder cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 30-04-2024
- First CTIS Authorization Date
- 20-05-2024
Trial design
Phase I trial across 15 sites in France, Spain.
- Target Sample Size
- 768
Recruitment
- Planned Sample Size
- 768
- Recruitment Window Months
- 84
Geography
- Total Number Of Sites
- 15
- Total Number Of Participants
- 238
France
- Earliest CTIS Part Ii Submission Date
- 09-04-2024
- Latest Decision Or Authorization Date
- 25-03-2026
- Processing Time Days
- 715
- Number Of Sites
- 5
- Number Of Participants
- 150
Sites
- Site Name
- Centre Hospitalier Universitaire D'Angers
- Department Name
- Service de Pneumologie
- Principal Investigator Name
- Youssef Oulkhouir
- Principal Investigator Email
- youssef.Oulkhouir@chu-angers.fr
- Contact Person Name
- Youssef Oulkhouir
- Contact Person Email
- youssef.Oulkhouir@chu-angers.fr
- Site Name
- Centre Hospitalier Universitaire De Poitiers
- Department Name
- Service d'Oncologie Méicale
- Principal Investigator Name
- Nicolas Isambert
- Principal Investigator Email
- nicolas.isambert@chu-poitiers.fr
- Contact Person Name
- Nicolas Isambert
- Contact Person Email
- nicolas.isambert@chu-poitiers.fr
- Site Name
- Centre Antoine Lacassagne
- Department Name
- Département d'Oncologie Médicale
- Principal Investigator Name
- Esma Saada-Bouzid
- Principal Investigator Email
- esma.saada-bouzid@nice.unicancer.fr
- Contact Person Name
- Esma Saada-Bouzid
- Contact Person Email
- esma.saada-bouzid@nice.unicancer.fr
- Site Name
- Institut De Cancerologie De Lorraine
- Department Name
- Département d'Oncologie Médicale
- Principal Investigator Name
- Aurélien Lambert
- Principal Investigator Email
- a.lambert@nancy.unicancer.fr
- Contact Person Name
- Aurélien Lambert
- Contact Person Email
- a.lambert@nancy.unicancer.fr
- Site Name
- Institut Gustave Roussy
- Department Name
- Département d’Innovation Thérapeutique et d’Essais, Précoces (DITEP)
- Principal Investigator Name
- Antoine Hollebecque
- Principal Investigator Email
- antoine.hollebecque@gustaveroussy.fr
- Contact Person Name
- Antoine Hollebecque
- Contact Person Email
- antoine.hollebecque@gustaveroussy.fr
Spain
- Earliest CTIS Part Ii Submission Date
- 09-04-2024
- Latest Decision Or Authorization Date
- 23-03-2026
- Processing Time Days
- 713
- Number Of Sites
- 10
- Number Of Participants
- 88
Sites
- Site Name
- Hospital De Jerez De La Frontera
- Department Name
- UGC Oncologia Medica
- Principal Investigator Name
- Jesus Corral
- Principal Investigator Email
- jesuscorraljaime@hotmail.com
- Contact Person Name
- Jesus Corral
- Contact Person Email
- jesuscorraljaime@hotmail.com
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Unidad de Ensayos Clínicos START Madrid # CIOCC
- Principal Investigator Name
- Emiliano Calvo
- Principal Investigator Email
- emiliano.calvo@startmadrid.com
- Contact Person Name
- Emiliano Calvo
- Contact Person Email
- emiliano.calvo@startmadrid.com
- Site Name
- Hospital Quironsalud Malaga
- Department Name
- Oncología Médica
- Principal Investigator Name
- Manuel Cobo
- Principal Investigator Email
- manuelcobodols@yahoo.es
- Contact Person Name
- Manuel Cobo
- Contact Person Email
- manuelcobodols@yahoo.es
- Site Name
- Hospital Quironsalud Barcelona
- Department Name
- Oncología Médica. Unidad NEXT Oncology
- Principal Investigator Name
- Omar Saavedra
- Principal Investigator Email
- osaavedra@nextoncology.eu
- Contact Person Name
- Omar Saavedra
- Contact Person Email
- osaavedra@nextoncology.eu
- Site Name
- Hospital Hm Nou Delfos
- Department Name
- Unidad de Ensayos Clínicos START Barcelona
- Principal Investigator Name
- Tatiana Hernandez
- Principal Investigator Email
- Tatiana.hernandez@start-barcelona.com
- Contact Person Name
- Tatiana Hernandez
- Contact Person Email
- Tatiana.hernandez@start-barcelona.com
- Site Name
- Hospital General Universitario De Elche
- Department Name
- Servicio de Oncología Médica
- Principal Investigator Name
- Javier David Benitez-Fuentes
- Principal Investigator Email
- javierdavidbenitezfuentes@gmail.com
- Contact Person Name
- Javier David Benitez-Fuentes
- Contact Person Email
- javierdavidbenitezfuentes@gmail.com
- Site Name
- Vall D Hebron Institute Of Oncology
- Department Name
- Unidad Investigacion Terapia Molecular - VHIO
- Principal Investigator Name
- Elena Garralda
- Principal Investigator Email
- egarralda@vhio.net
- Contact Person Name
- Elena Garralda
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Hospital Universitario Ramon Y Cajal
- Department Name
- Servicio de Oncología Médica
- Principal Investigator Name
- Federico Longo
- Principal Investigator Email
- federico.longo@salud.madrid.org
- Contact Person Name
- Federico Longo
- Contact Person Email
- federico.longo@salud.madrid.org
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Oncologia
- Principal Investigator Name
- Luis Paz-Ares Rodriguez
- Principal Investigator Email
- lpazaresr@seom.org
- Contact Person Name
- Luis Paz-Ares Rodriguez
- Contact Person Email
- lpazaresr@seom.org
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Servicio de Oncologia
- Principal Investigator Name
- Fernando Rivera
- Principal Investigator Email
- Fernando.rivera@scsalud.es
- Contact Person Name
- Fernando Rivera
- Contact Person Email
- Fernando.rivera@scsalud.es
Sponsor
Primary sponsor
- Full Name
- Seagen Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- Sigvotatug Vedotin
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)